Sugi Predict

Sugi Predict / Compounds / SCHEMBL37778

SCHEMBL37778

SCHEMBL37778

CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B10 O60218 4/20 1.00
▸ AKR1B1 P15121 4/20 1.00
▸ GPBAR1 Q8TDU6 2/20 1.00
▸ CYP3A4 P08684 3/20 0.70
▸ SHBG P04278 2/20 0.70
▸ CYP19A1 P11511 2/20 0.70
▸ NR3C1 P04150 1/20 0.70
▸ PGR P06401 1/20 0.70
▸ SERPINA6 P08185 1/20 0.70
▸ NR3C2 P08235 1/20 0.70
▸ AR P10275 1/20 0.70
▸ HSD17B10 Q99714 1/20 0.70
▸ MGAM O43451 1/20 0.70
▸ GABRP O00591 4/20 0.63
▸ GABRD O14764 4/20 0.63
▸ GABRA1 P14867 4/20 0.63
▸ GABRB1 P18505 4/20 0.63
▸ GABRG2 P18507 4/20 0.63
▸ GABRB3 P28472 4/20 0.63
▸ GABRA5 P31644 4/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18373741 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL13487248 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL19156379 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL14007476 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL12242383 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL23699767 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL17776486 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL12646116 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL675417 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG
SCHEMBL13988206 1.00 AKR1B10 (1.00) AKR1B10AKR1B1GPBAR1CYP3A4SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118731248-B Establishment method and application of reference GC-MS fingerprint of Juanbi decoction substance 广西中医药大学百年乐制药有限公司 2025-05-23 — — CN claimed
CN-119950517-A Ganaxolone for the treatment of tuberous sclerosis 马瑞纳斯制药公司 2025-05-09 — — CN claimed
US-20240374614-A1 GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX IMMEDICA PHARMA US INC. 2024-11-14 — — US claimed
CN-118731248-A Establishment method and application of reference GC-MS fingerprint of Juanbi decoction substance 广西中医药大学百年乐制药有限公司 2024-10-01 — — CN claimed
WO-2024175760-A1 METHODS FOR THE TREATMENT OF ENDOMETRIOSIS Institut National de la Santé et de la Recherche Médicale (FR) 2024-08-29 — — WO claimed
EP-3277285-B1 ESTRIOL FOR REDUCING CORTICAL GRAY MATTER ATROPHY UNIV CALIFORNIA (US) 2024-07-17 — — EP claimed
US-20240226189-A1 MICROBIOME MICROORGANISM AND USES THEREOF BIOMICA LTD. (IL) 2024-07-11 — — US claimed
US-11965199-B2 21-hydroxylation of steroids SANOFI (FR) 2024-04-23 — — US claimed
EP-4337234-A1 MICROBIOME MICROORGANISM AND USES THEREOF Biomica Ltd. (IL) 2024-03-20 — — EP claimed
CN-117396597-A Microbiome microorganisms and uses thereof 生物米卡有限公司 2024-01-12 — — CN claimed
EP-2464653-A2 METHOD FOR MAKING 3 -HYDROXY, 3 - METHYL-5 -PREGNAN-20-ONE (GANAXOLONE) Marinus Pharmaceuticals, Inc. (US) 2012-06-20 — — EP claimed
WO-2011120044-A1 CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE DUKE UNIVERSITY (US) 2011-09-29 — — WO claimed
WO-2011019821-A2 METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE) MARINUS PHARMACEUTICALS, INC. (US) 2011-02-17 — — WO claimed
US-20110040112-A1 METHOD FOR MAKING 3A-HYDROXY, 3B- SUBSTITUTED-5A-PREGNAN-20-ONES MARINUS PHARMACEUTICALS, INC. (US) 2011-02-17 — — US claimed
EP-0745121-B1 MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE AND MOLECULAR SWITCH FOR GENE THERAPY BAYLOR COLLEGE MEDICINE (US) 2007-06-20 — — EP claimed
US-6844333-B1 Method of treating atherosclerosis THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2005-01-18 — — US claimed
US-6740500-B1 Method of screening for non-steroidal neuropsychiatric agents DAVIS JOHN M (US) 2004-05-25 — — US claimed
US-20030220286-A1 System for regulation of transgene expression GENETRONICS, INC. 2003-11-27 — — US claimed
US-5439900-A Synergistic mixture of steroid and alcohol BUKUSOGLU CUNEYT (US) 1995-08-08 — — US claimed
US-4908358-A Inhibition of immune clearance using progesterone analogues TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1990-03-13 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374614-A1 GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX CYP17A1, HSD17B7, HSD17B11 AKR1B10 454/4885AKR1B1 1577/4885GPBAR1 1519/4885
US-20110040112-A1 METHOD FOR MAKING 3A-HYDROXY, 3B- SUBSTITUTED-5A-PREGNAN-20-ONES CYP17A1, CYP21A2, HSD17B7 AKR1B10 124/4885AKR1B1 148/4885GPBAR1 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.